Cure My Disease

Don't miss your cure!

 Log in / Sign up

Triple-Drug immunotherapy cocktail shows promise in advanced tumors

NCT ID NCT03459222

Completed Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested whether combining the experimental drug relatlimab with other immunotherapies (nivolumab plus either BMS-986205 or ipilimumab) is safe and can shrink tumors in people with advanced solid cancers. A total of 229 participants with various incurable, advanced tumors were enrolled. The main goals were to check for serious side effects and to see how many patients had their tumors shrink or stabilize.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
relatlimab (an experimental immunotherapy) combined with nivolumab, BMS-986205, or ipilimumab
What this could lead to
If successful, this could point toward new combination immunotherapy options for people with advanced cancers that are hard to treat.
What could go wrong
This is an early-phase trial focused on safety, so it is too soon to know if these combinations will work better than existing treatments. Side effects from combining multiple immunotherapies can be severe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER

Contacts and locations

Locations

  • Local Institution - 0001

    Germantown, Tennessee, 38138, United States

  • Local Institution - 0003

    Aurora, Colorado, 80045, United States

  • Local Institution - 0004

    Baltimore, Maryland, 21231, United States

  • Local Institution - 0005

    St Louis, Missouri, 63110, United States

  • Local Institution - 0006

    Duarte, California, 91010, United States

  • Local Institution - 0007

    Zurich, 8091, Switzerland

  • Local Institution - 0008

    Lausanne, 1011, Switzerland

  • Local Institution - 0009

    Naples, 80131, Italy

  • Local Institution - 0010

    Forlì, 47014, Italy

  • Local Institution - 0011

    Nedlands, Western Australia, 6009, Australia

  • Local Institution - 0012

    Wollstonecraft, New South Wales, 2065, Australia

  • Local Institution - 0013

    Headington, OX3 7LE, United Kingdom

  • Local Institution - 0014

    Newcastle upon Tyne, NE7 7DN, United Kingdom

  • Local Institution - 0015

    Villejuif, 94800, France

  • Local Institution - 0016

    Toulouse, 31059, France

  • Local Institution - 0017

    Marseille, 13385, France

  • Local Institution - 0018

    Madrid, 28050, Spain

  • Local Institution - 0019

    Barcelona, 08036, Spain

  • Local Institution - 0020

    Pamplona, 31008, Spain

  • Local Institution - 0021

    Madrid, 28041, Spain

  • Local Institution - 0022

    Málaga, 29011, Spain

  • Local Institution - 0023

    Rome, 00144, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.